Clinical Trials Logo

Psoriasis Vulgaris clinical trials

View clinical trials related to Psoriasis Vulgaris.

Filter by:

NCT ID: NCT06414382 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

PSODEEP2 Pilot Study on Koebner Induction in Psoriasis

PSODEEP2PIL
Start date: May 7, 2024
Phase: N/A
Study type: Interventional

Patients (n=15) with skin psoriasis, minimum age 18 years, without systemic immunomodulatory treatment will be subject to Koebner induction on arms and legs given that they have given written consent and that they have self-reported Koebner.

NCT ID: NCT06398106 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Proactive TDM Versus Standard Use of Biologics in Psoriasis

HELIOS
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and higher patients' treatment satisfaction while striving for the best clinical response.

NCT ID: NCT06257641 Recruiting - Obesity Clinical Trials

Impact of the Mediterranean Diet on Patients With Psoriasis

MEDIPSO
Start date: October 4, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine the effect of a high-intensity Mediterranean diet intervention over 16 weeks in a group of patients with mild to moderate psoriasis in terms of skin improvement as measured by PASI. In addition, the aim of this study will be to gather the necessary information for a larger and more extended clinical trial in the future. Participants will be provided with dietary education for the implementation of the Mediterranean diet, supported by a monthly follow-up by nutritionists with experience in the field. Researchers will compare the effect of the Mediterranean diet on these patients to a control group provided with standard recommendations for a low-fat diet with no monitoring by nutritionists.

NCT ID: NCT06203470 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Botox Versus Tacrolimus in Psoriasis Vulgaris

Start date: June 2024
Phase: Phase 4
Study type: Interventional

Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3%. Besides, it could have profound implications on the patients' psychological state and quality of life. It is presented by erythematous, scaly plaques over the preferred sites. The pathogenesis of this highly complex disease is still far from being fully understood. Keratinocytes' hyperproliferation and immune system dysfunctions are well recognized contributors, with numerous treatments targeting these unique immunologic dysfunctions.

NCT ID: NCT06191042 Recruiting - Psoriatic Arthritis Clinical Trials

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

NCT ID: NCT06064084 Completed - Psoriasis Vulgaris Clinical Trials

Incretin Effect in Patients With Psoriasis and Controls

Start date: September 11, 2011
Phase:
Study type: Observational

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

NCT ID: NCT06042647 Completed - Psoriasis Vulgaris Clinical Trials

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Start date: July 13, 2023
Phase: Phase 4
Study type: Interventional

The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.

NCT ID: NCT06011083 Completed - Psoriasis Vulgaris Clinical Trials

Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

comparing the clinical efficacy of topical ointment containing calcipotriol and betamethasone dipropionate used alone with the simultaneous use of fractional carbon dioxide laser and the same topical ointment containing these two ingredients as treatment modalities for plaque psoriasis. Additionally, looking into how both therapy modalities affect individuals with psoriasis in terms of how their quality of life is improved.

NCT ID: NCT05906498 Recruiting - Psoriasis Vulgaris Clinical Trials

Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris

Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

This study aims to assess the effect of adding N-acetyl cysteine (NAC) alone or in combination with Vitamin E to conventional therapy in improving the clinical outcome, oxidative stress, and inflammation in patients with mild psoriasis vulgaris

NCT ID: NCT05892640 Recruiting - Psoriasis Vulgaris Clinical Trials

Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Psoriasis presents an independent cardiovascular risk factor characterized by chronic low-grade systemic inflammation and oxidative stress which altogether might lead to endothelial dysfunction. It has been reported that increased oxidative stress has a pivotal role in high dietary sodium-induced endothelial dysfunction. Previous studies on sodium accumulation in psoriatic skin lesions and the sodium-induced augmentation in Th17 immune response, raise the question on the complex interplay between sodium and psoriasis, especially in the context of cardiovascular morbidity. This study aimed to investigate the effect of a 2-week low-salt diet on endothelium-dependent and endothelium-independent cutaneous microvascular vasodilation and Th17-Mediated Inflammation in patients with psoriasis vulgaris.